Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Hereditary Angioedema Therapeutic Market Overview

Hereditary angioedema is a rare autosomal dominant disorder caused by deficient or dysfunctional C1 esterase inhibitor protein, leading to recurrent swelling attacks of the skin, abdomen, face, and larynx. The market was valued at USD 3.41 Billion in 2025 and is expanding steadily with the rising adoption of prophylactic treatments, growing research investments, favorable regulatory support, and the development of innovative plasma-derived and monoclonal antibody therapies. Increasing healthcare access and strategic collaborations among biopharmaceutical companies are further supporting market growth.

Hereditary Angioedema Therapeutic Market Growth Drivers

Rising Disease Prevalence is Likely to Accelerate the Market Expansion

Increasing awareness of hereditary angioedema and advancements in diagnostic capabilities are significantly driving the growth of the market. Greater recognition of recurrent swelling symptoms among healthcare professionals has improved early diagnosis and treatment adoption. According to Healio, hereditary angioedema affects approximately one person per 50,000 individuals globally, while a 2024 systematic review estimated a prevalence ranging from 0.13 to 1.60 cases per 100,000 people. The growing identification of diagnosed patient populations is supporting higher demand for targeted therapies and encouraging continued therapeutic innovation and market expansion.

Hereditary Angioedema Therapeutic Market Trends

The market is witnessing several trends, including targeted biologics and convenient prophylactic treatment advancements.

Targeted Factor XIIa Inhibition is Likely to Boost the Market Growth

The growing focus on targeted prophylactic therapies with convenient dosing regimens is emerging as a significant trend in the market. For instance, in June 2025, CSL announced the U.S. Food and Drug Administration approval of ANDEMBRY® (garadacimab-gxii), a once-monthly prophylactic hereditary angioedema treatment targeting factor XIIa. The therapy demonstrated a substantial reduction in hereditary angioedema attacks and enhanced long-term disease control. Such advancements are expected to improve treatment adherence, expand therapeutic options, and accelerate the overall market growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Hereditary Angioedema Therapeutic Market Segmentation

Hereditary Angioedema Therapeutic Market Share

C1 Esterase Inhibitors Segment Likely to Lead the Market by Drug Class

The market is segmented by drug class into C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, kallikrein inhibitors, and others. Among these, C1 esterase inhibitors are expected to lead the market owing to their proven effectiveness in preventing and treating hereditary angioedema attacks, along with their widespread clinical acceptance and availability of advanced formulations. The growing preference for targeted therapies, rising diagnosis rates, and increasing awareness regarding long-term disease management are further supporting segment expansion. In addition, favorable treatment outcomes and continued focus on improving patient quality of life are expected to strengthen the dominance of this segment over the forecast period.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Hereditary Angioedema Therapeutic Market Analysis by Region

Among all the regions, the United States is expected to witness significant growth in the market due to advanced healthcare infrastructure, strong regulatory support, and increasing adoption of innovative therapies for rare diseases. For instance, in August 2025, the U.S. Food and Drug Administration approved Dawnzera by Ionis Pharmaceuticals as the first RNA-targeted prophylactic therapy for hereditary angioedema. According to the company’s Phase III OASIS-HAE trial data, the therapy reduced monthly attack rates by 81%, supporting continued market growth through therapeutic innovation and improved patient outcomes.

Leading Players in the Hereditary Angioedema Therapeutic Market

Key Questions Answered in the Hereditary Angioedema Therapeutic Market Report

• What was the hereditary angioedema therapeutic market value in 2025?
• What is the market forecast outlook for 2026-2035?
• What major factors aid demand for the hereditary angioedema therapeutic market?
• How has the market performed and how is it expected to perform ahead?
• What are the major drivers, opportunities, and restraints?
• What are the major hereditary angioedema therapeutic market trends?
• Which drug class is expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which patient type is expected to lead the market?
• Which route of administration is anticipated to drive the market segment?
• Which distribution channel is expected to dominate the market segment?
• Who are the key players in the hereditary angioedema therapeutic market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, mergers, and acquisitions shaping market dynamics?